These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26690800)

  • 1. Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.
    Plotegher N; Bubacco L
    Ageing Res Rev; 2016 Mar; 26():62-71. PubMed ID: 26690800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
    J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal.
    Zhang S; Eitan E; Wu TY; Mattson MP
    Neurobiol Aging; 2018 Jan; 61():52-65. PubMed ID: 29035751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired aldehyde detoxification exacerbates motor deficits in an alpha-synuclein mouse model of Parkinson's disease.
    Martinez PA; Martinez VE; Rani S; Murrell M; Javors M; Gelfond J; Doorn JA; Fernandez E; Strong R
    Brain Behav; 2023 Sep; 13(9):e3150. PubMed ID: 37452461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.
    Plotegher N; Berti G; Ferrari E; Tessari I; Zanetti M; Lunelli L; Greggio E; Bisaglia M; Veronesi M; Girotto S; Dalla Serra M; Perego C; Casella L; Bubacco L
    Sci Rep; 2017 Jan; 7():40699. PubMed ID: 28084443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
    Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
    PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
    Jinsmaa Y; Cooney A; Sullivan P; Sharabi Y; Goldstein DS
    Neurosci Lett; 2015 Mar; 590():134-7. PubMed ID: 25637699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The catecholaldehyde hypothesis: where MAO fits in.
    Goldstein DS
    J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase.
    Marchitti SA; Deitrich RA; Vasiliou V
    Pharmacol Rev; 2007 Jun; 59(2):125-50. PubMed ID: 17379813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
    Goldstein DS; Kopin IJ; Sharabi Y
    Pharmacol Ther; 2014 Dec; 144(3):268-82. PubMed ID: 24945828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
    Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
    J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of α-synuclein on membrane permeability and synaptic transmission: a clue to neurodegeneration?
    Surguchev A; Surguchov A
    J Neurochem; 2015 Mar; 132(6):619-21. PubMed ID: 25739983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
    Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
    Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.
    Näsström T; Wahlberg T; Karlsson M; Nikolajeff F; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2009 Jan; 378(4):872-6. PubMed ID: 19070597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
    Werner-Allen JW; DuMond JF; Levine RL; Bax A
    Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
    Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.